Table 3. Univariate and multivariate Cox proportional hazard models for overall survival (OS) and progression-free survival (PFS) in all EOC patients.
| OS | PFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | p* | HR (95% CI) | p* | HR (95% CI) | p* | HR (95% CI) | p* | |
| miR-520g | ||||||||
| Low | - | - | - | - | ||||
| High | 5.41 (3.71, 9.06) | < 0.001* | 6.16 (3.15, 11.01) | 0.003* | 5.32 (2.03, 9.08) | < 0.001* | 4.05 (1.43, 11.14) | 0.036* |
| Age | ||||||||
| < 50 | - | - | - | - | ||||
| ≥ 50 | 1.76 (0.98, 4.35) | 0.436 | 1.17 (0.89, 2.43) | 0.691 | ||||
| Ascites | ||||||||
| < 100 | - | - | - | - | ||||
| ≥ 100 | 1.36 (0.83, 2.28) | 0.076 | 0.94 (0.79, 1.86) | 0.447 | ||||
| Serum CA-125 level | ||||||||
| < 35 | - | - | - | - | ||||
| ≥ 35 | 1.59 (1.04, 1.94) | 0.654 | 2.36 (1.76, 3.89) | 0.271 | ||||
| Lymph node metastasis | ||||||||
| Negative | - | - | - | - | ||||
| Positive | 5.34 (3.75, 10.01) | 0.023* | 4.17 (1.68, 9.78) | 0.015* | 3.41 (1.57, 11.14) | 0.016* | 3.45 (1.24, 7.52) | 0.007* |
| Tumor differentiation | ||||||||
| G1 | - | - | - | - | ||||
| G2 | 4.53 (1.67, 8.52) | 0.043* | 3.03 (0.58, 8.02) | 0.071 | 2.51 (1.82, 5.77) | 0.041* | 1.40 (0.72, 3.70) | 0.032* |
| G3 | 3.98 (2.79, 10.01) | < 0.001* | 2.56 (1.35, 9.01) | 0.031* | 5.65 (1.44, 10.32) | 0.028* | 2.46 (1.63, 6.47) | < 0.001* |
| Histology type | ||||||||
| Serous | - | - | - | - | ||||
| Mucinous | 4.14 (2.72, 9.59) | 0.667 | 4.03 (2.15, 6.78) | 0.534 | ||||
| Endometrioid | 3.12 (1.17, 6.78) | 0.335 | 2.97 (1.56, 5.74) | 0.721 | ||||
| Clear cell | 2.01 (1.48, 4.91) | 0.218 | 2.67 (1.83, 5.46) | 0.054 | ||||
| Residual tumor size | ||||||||
| < 1 cm | - | - | - | - | ||||
| ≥ 1 cm | 4.02 (2.97, 8.41) | 0.014* | 2.31 (1.52, 5.43) | < 0.001* | 4.21 (2.48, 8.97) | 0.027* | 3.11 (1.68–8.45) | 0.047* |
| FIGO stage | ||||||||
| I–II | - | - | - | - | ||||
| III–IV | 3.59 (2.96, 9.15) | 0.021* | 2.41 (1.38, 5.17) | 0.007* | 4.98 (3.37, 6.46) | 0.025* | 3.56 (2.05, 11.21) | < 0.001 |
| Chemotherapy | ||||||||
| TP | - | - | ||||||
| PAC | 1.34 (0.97–2.85) | 0.448 | 1.37 (1.02–1.91) | 0.524 | 0.067 | |||
HR, hazard ratio; CI, confidence interval.
*
p < 0.05 indicated that the 95% CI of HR was not including 1.
FIGO: International Federation of Gynecology and Obstetrics.
TP: cisplatin and paclitaxel, PAC: cisplatin, epirubicin, and cyclophosphamide.